This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignee: Yeda Research and Develpment & Co. Ltd. Active years: 1999-2006.
Company Filing History:
Years Active: 1999-2006
Title: Innovations by Michael Deckmann in Schizophrenia Diagnosis
Introduction
Michael Deckmann is an accomplished inventor based in Guebwiller, France. He has made significant contributions to the field of medical diagnostics, particularly in the diagnosis of schizophrenia. With a total of 3 patents to his name, Deckmann's work focuses on innovative methods that enhance the accuracy of schizophrenia diagnosis.
Latest Patents
One of Deckmann's latest patents is an assay for the diagnosis of schizophrenia based on a new peptide. This invention involves peptides that bind to antibodies found in elevated levels in the body fluids of schizophrenic patients, while these antibodies are either present at lower levels or absent in non-schizophrenic individuals. The antigenic epitope of these peptides is predicted to have a core of hydrophobic amino acids surrounded by positively charged amino acids. This innovative approach is useful for diagnosing schizophrenia in individuals.
Another notable patent is a skin test for schizophrenia. This diagnostic method involves injecting a preparation comprising platelet-derived proteins or fractions with a pI above about 6.5 into a subject. The occurrence of a delayed type hypersensitivity (DTH) reaction at the injection site is then determined. A positive DTH reaction indicates a high likelihood of schizophrenia in the tested subject. This patent also includes the protein preparation used in the diagnostic method, as well as a method for its preparation and a kit for use in the diagnosis of schizophrenia.
Career Highlights
Michael Deckmann is associated with Yeda Research and Development Co. Ltd., where he continues to innovate in the field of medical diagnostics. His work has garnered attention for its potential to improve the lives of individuals affected by schizophrenia.
Collaborations
Deckmann collaborates with Meir Shinitzky, further enhancing the research and development efforts in their field.
Conclusion
Michael Deckmann's contributions to the diagnosis of schizophrenia through innovative patents demonstrate his commitment to advancing medical science. His work not only highlights the importance of accurate diagnosis but also showcases the potential for new diagnostic methods to improve patient outcomes.